KR950702528A - 엔^지(n^g)-모노메틸-엘(l)-아르기닌 염화수소 유도체 및 패혈증성 쇼크의 치료에 있어서의 이들의 용도, (n^g-monomethyl-l-arginine hydrochloride derivatives and their use in the treatment of septic shock) - Google Patents
엔^지(n^g)-모노메틸-엘(l)-아르기닌 염화수소 유도체 및 패혈증성 쇼크의 치료에 있어서의 이들의 용도, (n^g-monomethyl-l-arginine hydrochloride derivatives and their use in the treatment of septic shock)Info
- Publication number
- KR950702528A KR950702528A KR1019950700192A KR19950700192A KR950702528A KR 950702528 A KR950702528 A KR 950702528A KR 1019950700192 A KR1019950700192 A KR 1019950700192A KR 19950700192 A KR19950700192 A KR 19950700192A KR 950702528 A KR950702528 A KR 950702528A
- Authority
- KR
- South Korea
- Prior art keywords
- monomethyl
- arginine
- hydrogen chloride
- salt
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본 발명은 (S)-N5-[이미노(메틸아미노)메틸]오르니틴 염화수소, 이것을 함유하는 약학적 조성물, 의학 분야에 있어서의 이것의 용도, 및 이것의 제조방법에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (14)
- 거의 순수한 염으로서의 NG-모노메틸-L-아르기닌 염화수소.
- 고체 형태의 NG-모노메틸-L-아르기닌 염화수소.
- 결정성 형태의 NG-모노메틸-L-아르기닌 염화수소.
- 제3항에 있어서, 약 205℃에서 용융되는 동일 구조 형태의 NG-모노메틸-L-아르기닌 염화수소.
- 제3항에 있어서, 약 205℃에서 용융되는 동일 구조 형태의 NG-모노메틸-L-아르기닌 염화수소.
- NG-모노메틸-L-아르기닌과 염산을 반응시키며, 이어서 그 염화수소 염을 결정화시키는 것을 포함하는 결정성 NG-모노메틸-L-아르기닌 염화수소의 제조 방법.
- 제6항에 있어서, NG-모노메틸-L-아르기닌 대 염산의 몰비가 1 : 1 내지 1 : 5인 방법.
- NG-모노메틸-L-아르기닌의 염화수소 염 이외의 NG-모노메틸-L-아르기닌의 염화수소 염과 염산을 반응시키며, 이온을 형성하는 초기 염을 제거한 후, 그 염화수소 염을 결정화시키는 것을 포함하는 NG-모노메틸-L-아르기닌의 염화수소의 제조 방법.
- 제6항, 제7항 또느 제8항중 어느 한 항에 있어서, NG-모노메틸-L-아르기닌의 염화수소의 하나 또는 그 이상의 결정과 함께 시이드화 시킴으로써 결정화 공정을 돕는 방법.
- NG-모노메틸-L-아르기닌의 염화수소, 이에 대한 하나 또는 그 이상의 약학적 허용 담체, 및 선택적으로 하나 또는 그 이상의 기타 치료제 성분을 함유하는 약학적 제제.
- 제10항에 있어서, 물에 용해되고, 이것의 pka로 완충되며, 제1항에 내지 제5항 중 어느 한항에 의한 NG-모노메틸-L-아르기닌의 염화수소를 함유하는 약학적 제제.
- 패형증성 쇼크의 치료 또는 예방을 위한 약제로서의 NG-모노메틸-L-아르기닌의 염화수소의 용도.
- 치료에 효과적인 양의 NG-모노메틸-L-아르기닌의 염화수소를 투여하는 것을 포함하는 패혈증성 쇼크의 치료 또는 예방 방법.
- ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9215816.1 | 1992-07-24 | ||
| GB929215816A GB9215816D0 (en) | 1992-07-24 | 1992-07-24 | Arginine derivatives |
| PCT/GB1993/001563 WO1994002453A1 (en) | 1992-07-24 | 1993-07-23 | Ng-monomethyl-l-arginine hydrochloride derivatives and their use in the treatment of septic shock |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR950702528A true KR950702528A (ko) | 1995-07-29 |
Family
ID=10719277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950700192A KR950702528A (ko) | 1992-07-23 | 1993-07-23 | 엔^지(n^g)-모노메틸-엘(l)-아르기닌 염화수소 유도체 및 패혈증성 쇼크의 치료에 있어서의 이들의 용도, (n^g-monomethyl-l-arginine hydrochloride derivatives and their use in the treatment of septic shock) |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP0651741B1 (ko) |
| JP (1) | JP2878844B2 (ko) |
| KR (1) | KR950702528A (ko) |
| CN (1) | CN1087624A (ko) |
| AT (1) | ATE148451T1 (ko) |
| CA (1) | CA2140852A1 (ko) |
| CY (1) | CY2085B1 (ko) |
| CZ (1) | CZ8095A3 (ko) |
| DE (1) | DE69307894T2 (ko) |
| DK (1) | DK0651741T3 (ko) |
| ES (1) | ES2098051T3 (ko) |
| GB (1) | GB9215816D0 (ko) |
| GR (1) | GR3022773T3 (ko) |
| HU (1) | HU210876A9 (ko) |
| IL (1) | IL106463A (ko) |
| MX (1) | MX9304466A (ko) |
| NO (1) | NO302360B1 (ko) |
| NZ (1) | NZ254865A (ko) |
| PL (1) | PL307238A1 (ko) |
| RU (1) | RU95105249A (ko) |
| SG (1) | SG46425A1 (ko) |
| SK (1) | SK8295A3 (ko) |
| WO (1) | WO1994002453A1 (ko) |
| ZA (1) | ZA935348B (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424447A (en) * | 1993-07-07 | 1995-06-13 | The Medical College Of Wisconsin Research Foundation, Inc. | Heme binding compounds and use thereof |
| GB9603522D0 (en) * | 1996-02-20 | 1996-04-17 | Wellcome Found | Chemical process |
| CA2514575A1 (en) * | 2003-01-31 | 2004-08-12 | Teijin Pharma Limited | Crystal of (23s)-1.alpha.-hydroxy-27-nor-25-methylenevitamin d3-26,23-lactone and process for producing the same |
| CN1724514B (zh) * | 2004-07-19 | 2010-06-09 | 上海依福瑞实业有限公司 | 一种l－高精氨酸盐酸盐的制备方法 |
| WO2007139897A1 (en) * | 2006-05-23 | 2007-12-06 | University Of Utah Research Foundation | Compositions and methods for the inhibition of endothelial nitric oxide synthase activity |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028627A (en) * | 1989-09-13 | 1991-07-02 | Cornell Research Foundation, Inc. | Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor |
-
1992
- 1992-07-24 GB GB929215816A patent/GB9215816D0/en active Pending
-
1993
- 1993-07-23 ES ES93917905T patent/ES2098051T3/es not_active Expired - Lifetime
- 1993-07-23 RU RU95105249/04A patent/RU95105249A/ru unknown
- 1993-07-23 SK SK82-95A patent/SK8295A3/sk unknown
- 1993-07-23 DK DK93917905.7T patent/DK0651741T3/da active
- 1993-07-23 DE DE69307894T patent/DE69307894T2/de not_active Expired - Fee Related
- 1993-07-23 EP EP93917905A patent/EP0651741B1/en not_active Expired - Lifetime
- 1993-07-23 JP JP6504312A patent/JP2878844B2/ja not_active Expired - Lifetime
- 1993-07-23 SG SG1996004597A patent/SG46425A1/en unknown
- 1993-07-23 KR KR1019950700192A patent/KR950702528A/ko not_active IP Right Cessation
- 1993-07-23 NZ NZ254865A patent/NZ254865A/en unknown
- 1993-07-23 CN CN93109375A patent/CN1087624A/zh active Pending
- 1993-07-23 MX MX9304466A patent/MX9304466A/es not_active IP Right Cessation
- 1993-07-23 CZ CZ9580A patent/CZ8095A3/cs unknown
- 1993-07-23 ZA ZA935348A patent/ZA935348B/xx unknown
- 1993-07-23 IL IL10646393A patent/IL106463A/en not_active IP Right Cessation
- 1993-07-23 CA CA002140852A patent/CA2140852A1/en not_active Abandoned
- 1993-07-23 AT AT93917905T patent/ATE148451T1/de not_active IP Right Cessation
- 1993-07-23 PL PL93307238A patent/PL307238A1/xx unknown
- 1993-07-23 WO PCT/GB1993/001563 patent/WO1994002453A1/en not_active Application Discontinuation
-
1995
- 1995-01-23 NO NO950248A patent/NO302360B1/no unknown
- 1995-06-02 HU HU95P/P00152P patent/HU210876A9/hu unknown
-
1997
- 1997-03-07 GR GR970400457T patent/GR3022773T3/el unknown
-
1999
- 1999-03-05 CY CY9902085A patent/CY2085B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL106463A0 (en) | 1993-11-15 |
| GB9215816D0 (en) | 1992-09-09 |
| NO950248D0 (no) | 1995-01-23 |
| JP2878844B2 (ja) | 1999-04-05 |
| MX9304466A (es) | 1994-04-29 |
| SK8295A3 (en) | 1995-07-11 |
| RU95105249A (ru) | 1996-10-27 |
| DK0651741T3 (da) | 1997-05-12 |
| AU669557B2 (en) | 1996-06-13 |
| CZ8095A3 (en) | 1995-10-18 |
| CN1087624A (zh) | 1994-06-08 |
| NO950248L (no) | 1995-01-23 |
| DE69307894T2 (de) | 1997-06-12 |
| DE69307894D1 (de) | 1997-03-13 |
| NO302360B1 (no) | 1998-02-23 |
| WO1994002453A1 (en) | 1994-02-03 |
| NZ254865A (en) | 1996-10-28 |
| ZA935348B (en) | 1995-01-23 |
| EP0651741A1 (en) | 1995-05-10 |
| PL307238A1 (en) | 1995-05-15 |
| GR3022773T3 (en) | 1997-06-30 |
| CY2085B1 (en) | 1999-03-05 |
| HU210876A9 (en) | 1995-09-28 |
| IL106463A (en) | 1998-08-16 |
| ES2098051T3 (es) | 1997-04-16 |
| CA2140852A1 (en) | 1994-02-03 |
| SG46425A1 (en) | 1998-02-20 |
| EP0651741B1 (en) | 1997-01-29 |
| ATE148451T1 (de) | 1997-02-15 |
| AU4715793A (en) | 1994-02-14 |
| JPH07509239A (ja) | 1995-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR940005636A (ko) | 트리아졸릴티오메틸티오 세팔로스포린 염산염, 그의 수화물 결정 및 이들의 제조방법 | |
| HUT51136A (en) | Process for producing pharmaceutical compositions for treating schisophreny, containing l-deprenil as active component | |
| HUT47217A (en) | Process for producing pharmaceutical compositions containing indol derivatives as active components | |
| UA41446C2 (uk) | Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі | |
| NZ246202A (en) | Amidino-substituted alpha-amino acid derivatives and pharmaceutical compositions | |
| CA2075876A1 (fr) | Nouveaux derives d'arylethylamines, leurs procedes de preparation et lescompositions pharmaceutiques qui les contiennent | |
| NO308792B1 (no) | Derivater av valproinsyre og 2-valproensyreamider, farmasøytisk sammensetning derav og deres anvendelse for fremstilling av et farmasøytisk preparat | |
| NO323815B1 (no) | Karbapenemantibiotikum,farmasoytisk preparat omfattende dette og fremgangsmate for stabilisering av karbapenemantibiotikum. | |
| PT86121B (pt) | Processo para a preparacao de sal de acido 2-{(2,6-diclorofenil)-amino}-benzeno-acetico com uma base organica ciclica e de composicoes farmaceuticas contendo o mesmo | |
| ES2078019T3 (es) | Amidas de alcanoil l-carnitina con aminoacidos y composiciones farmaceuticas que las contienen para promover regeneracion del tejido nervioso, inhibir degeneracion neuronal, mejorar el proceso de aprendimiento y memoria y para el tratamiento de coma. | |
| KR950702528A (ko) | 엔^지(n^g)-모노메틸-엘(l)-아르기닌 염화수소 유도체 및 패혈증성 쇼크의 치료에 있어서의 이들의 용도, (n^g-monomethyl-l-arginine hydrochloride derivatives and their use in the treatment of septic shock) | |
| RU97104483A (ru) | Соль янтарной кислоты 4-[2-амино-6-(циклопропиламино)-9н-пурин-9-ил]-2- циклопентен-1-метанола в качестве антивирусного агента | |
| HUT70531A (en) | Arylmorpholine derivatives, pharmaceutical compositions containing them as active agent and process for preparing them | |
| JPS6121528B2 (ko) | ||
| KR910002775A (ko) | 방향족 카복실산 아미드 | |
| KR900701278A (ko) | 바이러스 감염 치료용 담즙산 | |
| ATE169635T1 (de) | Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen | |
| EP0302836B1 (en) | Pharmaceutical compositions for topical use containing miocamycin | |
| BR9814496A (pt) | Composto, processos para a preparação de cristais de sementes da modificação termodinamicamente estável i de ramatroban, para a preparação de uma forma termodinamicamente estável de ramatroban, medicamento, e, uso de uma modificação termodinamicamente estável de ramatroban | |
| KR930023338A (ko) | 데포우 제제 | |
| KR880700805A (ko) | 기능성 유기 염기를 주제로 하는 뇌질환 치료용 제약 조성물 | |
| RU99100703A (ru) | Модифицированная форма гидрохлорида r(-)-n -(4,4-ди(3-метил-тиен-2-ил)бут-3- енил)-нипекотиновой кислоты | |
| KR890003755A (ko) | 7- (2- 메틸- 4- 아미노피롤리디닐)나프티리딘 및 퀴놀린 화합물 | |
| KR870010036A (ko) | 유기 아연 착화합물의 제조방법 및 활성 성분으로서 그를 함유하는 약학 조성물 | |
| KR890012961A (ko) | N-(저급알킬)-2-(3'-우레이도벤질)피롤리딘 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application | ||
| SUBM | Surrender of laid-open application requested |